Differentiating the Differentiation Syndrome Associated with IDH Inhibitors in AML.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 32554513.
- Also identified by DOI 10.1158/1078-0432.CCR-20-1820.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Isocitrate dehydrogenase (IDH) inhibitors have clinical activity in acute myeloid leukemia, in part, by differentiating blasts to mature myeloid cells. In the largest systematic analysis to date, differentiation syndrome was seen in 19% of patients treated with IDH inhibitors. Early recognition with uniform diagnostic criteria, as utilized in acute promyelocytic leukemia, may reduce subsequent complications.<i>See related article by Norsworthy et al., p. 4280</i>.
Medical subject headings
- Isocitrate Dehydrogenase
- Leukemia, Myeloid, Acute